12399456https://www.upal.com.my/zh/feeds/jobFeedKwongwahArray ( [0] => HTTP/1.1 200 OK [1] => Date: Sun, 25 May 2025 01:29:46 GMT [2] => Content-Type: text/xml; charset=utf-8 [3] => Connection: close [4] => Nel: {"success_fraction":0,"report_to":"cf-nel","max_age":604800} [5] => Report-To: {"endpoints":[{"url":"https:\/\/a.nel.cloudflare.com\/report\/v4?s=OWa29RZdoiFlRFd0ABrweq2o2nXogQ65xbP58yRJkoDqGyfYq%2BPHmfKUC56cu7Wvbaqxl%2FiUwdbXZdhRhgZpqGT4ApyemvXMNeXD0bB8x9SmOKirnfADLaYVLV7f%2BZfZ3RM%3D"}],"group":"cf-nel","max_age":604800} [6] => Server: cloudflare [7] => Vary: Accept-Encoding [8] => X-Powered-By: PHP/7.4.33 [9] => Cache-Control: no-cache, private [10] => Cf-Ray: 945143829ad3e557-KUL [11] => X-Frame-Options: SAMEORIGIN [12] => X-Xss-Protection: 1; mode=block [13] => X-Content-Type-Options: nosniff [14] => Referrer-Policy: no-referrer-when-downgrade [15] => Cf-Cache-Status: DYNAMIC [16] => Set-Cookie: UpalLiveSession=eyJpdiI6InlyZnNxYVRSbCtqSzNteXBDOEExQXc9PSIsInZhbHVlIjoiWTNtbE9GeHNrNG9FUmhxOG15eU0rQXFHMWo1NzdRUGpKRFNsbHVvMDVzaUxGWGtlaXhVb2FFKzMrT3hsNFVaVzdLZFpoNEJpNk5xQUh6bWpzYUIyYXc9PSIsIm1hYyI6Ijk4ZGY1YTZkOWQ5OWQ1YmJiZGM0NGVlMGViZDBiNmFhOGNmODJmOTQxNDZlYWVmY2IzZjczMzUxNTgyYzg5NjQifQ%3D%3D; HttpOnly; Path=/; Max-Age=94608000; Expires=Wed, 24 May 2028 00:44:30 GMT [17] => alt-svc: h3=":443"; ma=86400 [18] => server-timing: cfL4;desc="?proto=TCP&rtt=1141&min_rtt=955&rtt_var=633&sent=4&recv=6&lost=0&retrans=0&sent_bytes=3000&recv_bytes=756&delivery_rate=3032460&cwnd=252&unsent_bytes=0&cid=0562acde357d8835&ts=21&x=0" ) 789

美国吉利德科学公司研发的药物“瑞德西韦”，被认为可望抑制新型冠状病毒感染，中国科学家于周三已在武汉启动临床试验，用于治疗新冠肺炎患者。

媒体报导，主导瑞德西韦研发工作的是来自台湾的女科学家，也就是吉利德制药部门执行副总裁杨台莹。

根据吉利德网站介绍，杨台莹毕业于台湾大学化学系，也拥有南加州大学有机化学博士学位。

她领导吉利德的药物研发与制造部门，负责该公司研发与上市产品。在她的领导下，吉利德研发出全球第一款治疗HIV单锭药物，也将多于25种复方制剂研发成药品。

北京“中日友好医院”的王辰、曹彬团队于周三下午在武汉市金银潭医院宣布启动瑞德西韦治疗2019新型冠状病毒感染临床3期研究，首批试验761位患者。

---

// // // //